PL370842A1 - Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej - Google Patents

Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej

Info

Publication number
PL370842A1
PL370842A1 PL02370842A PL37084202A PL370842A1 PL 370842 A1 PL370842 A1 PL 370842A1 PL 02370842 A PL02370842 A PL 02370842A PL 37084202 A PL37084202 A PL 37084202A PL 370842 A1 PL370842 A1 PL 370842A1
Authority
PL
Poland
Prior art keywords
dopamin
selective
treatment
receptor agonists
sexual dysfunction
Prior art date
Application number
PL02370842A
Other languages
English (en)
Inventor
Der Graff Pieter Hadewijn Van
Christopher Peter Wayman
Andrew Douglas Baxter
Andrew Simon Cook
Stephen Kwok-Fung Wong
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL370842A1 publication Critical patent/PL370842A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL02370842A 2001-12-18 2002-12-10 Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej PL370842A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130219.9A GB0130219D0 (en) 2001-12-18 2001-12-18 Compounds for the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
PL370842A1 true PL370842A1 (pl) 2005-05-30

Family

ID=9927832

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370842A PL370842A1 (pl) 2001-12-18 2002-12-10 Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej

Country Status (15)

Country Link
US (1) US20060052435A1 (pl)
EP (1) EP1463508A1 (pl)
JP (2) JP4214057B2 (pl)
KR (1) KR20040068299A (pl)
CN (1) CN1617727A (pl)
AU (1) AU2002352372A1 (pl)
BR (1) BR0215064A (pl)
CA (1) CA2470624A1 (pl)
GB (1) GB0130219D0 (pl)
IL (1) IL162455A0 (pl)
MX (1) MXPA04006079A (pl)
NZ (1) NZ533513A (pl)
PL (1) PL370842A1 (pl)
WO (1) WO2003051370A1 (pl)
ZA (1) ZA200403906B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040089D1 (de) 1999-11-19 2008-10-09 Solvay Pharm Bv Menschliches homolog aus der familie der metalloproteasen
PL376452A1 (pl) * 2002-10-25 2005-12-27 Pharmacia & Upjohn Company Llc Zastosowanie związków typu heterocyklicznej aminyjako środków neuroochronnych
OA13014A (en) * 2002-12-10 2006-11-10 Pfizer Morpholine derivatives for use as dopamine agonists in the treatment of i.a sexual dysfunction.
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
JP4093588B2 (ja) * 2004-05-26 2008-06-04 ファイザー・インク 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
AU2005247699A1 (en) * 2004-05-27 2005-12-08 Pfizer Inc. Aminopyridine derivatives as selective dopamine D3 agonists
CN102264733B (zh) 2008-10-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
CN114113628A (zh) * 2021-11-08 2022-03-01 华东师范大学 多巴胺d2受体在嗅觉外周调控及制备治疗嗅觉异常药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
JPS5742862B2 (pl) * 1974-05-18 1982-09-10
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
US4929641B1 (en) * 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US5750646A (en) * 1987-09-24 1998-05-12 The Administrators Of The Tulane Educational Fund Bradykinin analogs with non-peptide bond
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5877277A (en) * 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5767236A (en) * 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5620959A (en) * 1990-07-31 1997-04-15 Glaxo Wellcome Inc. Bombesin antagonists
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9213215D0 (en) * 1992-06-20 1992-08-05 Wellcome Found Peptides
US5462926A (en) * 1992-07-27 1995-10-31 Biomeasure, Inc. Neuromedin B receptor antagonists which demonstrate selectivity
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
AU4844396A (en) * 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
US5849863A (en) * 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
FR2767825A1 (fr) * 1997-09-01 1999-02-26 Adir Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
IL157009A0 (en) * 2001-03-28 2004-02-08 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Also Published As

Publication number Publication date
KR20040068299A (ko) 2004-07-30
AU2002352372A1 (en) 2003-06-30
CA2470624A1 (en) 2003-06-26
EP1463508A1 (en) 2004-10-06
WO2003051370A8 (en) 2003-10-02
WO2003051370A1 (en) 2003-06-26
IL162455A0 (en) 2005-11-20
JP4214057B2 (ja) 2009-01-28
CN1617727A (zh) 2005-05-18
GB0130219D0 (en) 2002-02-06
BR0215064A (pt) 2004-10-13
JP2005516014A (ja) 2005-06-02
JP2008266338A (ja) 2008-11-06
ZA200403906B (en) 2005-06-22
US20060052435A1 (en) 2006-03-09
NZ533513A (en) 2006-04-28
MXPA04006079A (es) 2004-09-27

Similar Documents

Publication Publication Date Title
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
IL161041A0 (en) Mch antagonists for the treatment of obesity
PL377729A1 (pl) Sposób leczenia dysfunkcji seksualnej
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
HUP0201184A2 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
ZA200501308B (en) Agonism of the 5HT2a receptor for treatment of thermoregulatory dysfunction
IL146697A0 (en) SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
PL370842A1 (pl) Selektywni agoniści receptora dopaminowego D3 do leczenia dysfunkcji seksualnej
PL369850A1 (pl) Podstawione indole, sposób ich wytwarzania i ich zastosowanie do zwalczania bólu
AU2689502A (en) The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
IL154215A0 (en) Medicine for fighting against sexual dysfunction
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2002366272A8 (en) Edg-receptor agonist for the treatment of hypertension
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
HK1072934A (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
GB0111037D0 (en) Treatment of sexual dysfunction
GB0126904D0 (en) Treatment of sexual dysfunction
GB0109910D0 (en) Treatment of sexual dysfunction
AU2002315366A1 (en) Therapeutic treatment for sexual dysfunction

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)